


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/748,658
Filing Date	December 31, 2003
First Named Inventor	Mathiesen, Jacob
Art Unit	3767
Examiner Name	Gray, Phillip A.
Attorney Docket Number	GTI-5001-CP

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund
<input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	* Supp Transmittal (1 page) * Supp IDS Statement (2 pages) * Supp SB/08 Form (1 page) * Reference (1 item) * Return Postcard (1 item)
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	BioTechnology Law Group		
Signature			
Printed name	Daniel M. Chambers		
Date	September 26, 2003	Reg. No.	34,561

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Daniel M. Chambers	Date	September 26, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mathiesen, Iacob Examiner: Gray, Phillip A
Serial No.: 10/748,658 Group Art Unit: 3767
Filed: December 31, 2003 Docket: GTI-5001-CP
Title: Electroporation Device and Injection Apparatus

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (1)

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed material is brought to the attention of the Examiner for consideration in connection with the above-identified patent application.

Applicants respectfully request that the enclosed Supplemental Information Disclosure Statement be entered, and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8:

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop: AMENDMENT, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name Daniel M. Chambers
Signature 

September 26, 2005

Also, Applicants respectfully request that in patent application USSN 10/612,304, filed July 3, 2003, the Information Disclosure Statement, filed January 8, 2004, be incorporated and considered as part of the present application. As provided in 37 C.F.R. §1.98(d), copies of the documents listed the Information Disclosure Statement, except for EP 0460650, herein attached, are not being provided since they were previously cited by or submitted to the Patent Office in USSN. 10/612,304.

The listed document is being submitted in compliance with 37 CFR § 1.97(b), before the mailing date of the first office action on the merits.

If any fees are due, please contact the undersigned attorney at (858) 350-9690.

The Examiner is invited to contact the Applicants' Representative at (858) 350-9690 if there are any questions regarding this communication.

Respectfully submitted,



Daniel M. Chambers

Reg. No. 34,561

Date: September 16, 2004
BioTechnology Law Group
527 N. Highway 101, Suite E
Solana Beach, CA 92075-1173
Telephone: 858 350-9690
Facsimile: 858 350-9691
dan@biotechnologylawgroup.com

Substitute for form 1449A/PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

SEP 29 2006
PATENT & TRADEMARK OFFICE

Complete if Known	
Application Number	10/748,658
Filing Date	December 31, 2003
First Named Inventor	Mathiesen, Iacob
Group Art Unit	3767
Examiner Name	Gray, Phillip A

Sheet 1 of 1

Attorney Docket No: GTI-5001-CP

US PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	USP Document Number	Issued Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	4,882,127	21 Nov 1989	Rosenthal et al	
	A2.	4,341,735	27 Jul 1982	Seifried	
	A3.	3,645,692	29 Feb 1972	Stork et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	A4.	WO 98/43702	08 Oct 1998	Mathiesen, Iacob		
	A5.	WO 96/39226 A	12 Dec 1996	Genetronics, Inc.		
	A6.	WO 83/04309	12 Aug 1983	Ackermann et al		
	A7.	EP 0693951 B1	26 Aug 1998	Centre National De La Recherche Scientifique		
	A8.	EP 0460650 A3	12 Nov 1991	Labsystems OY		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A9.	Chastain, M. et al., "Antigen levels and antibody titers after DNA vaccination," <i>Journal of Pharmaceutical Science</i> 90(4):474-484 (2001)	
	A10.	Sanes, J. R., et al., "Selective expression of an acetylcholine receptor-lacZ transgene in synaptic nuclei of adult muscle fibers," <i>Development</i> 113:1181-1191 (1991)	

EXAMINER**DATE CONSIDERED**